ロード中...

Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer

High-grade serous ovarian cancer (HGSOC) is the predominant and most lethal histological type of epithelial ovarian cancer. During the last few years, several new treatment options with PARP inhibitors have emerged. The FDA has approved the PARP inhibitor olaparib (Lynparza™) as maintenance treatmen...

詳細記述

保存先:
書誌詳細
出版年:Oncotarget
主要な著者: Sahin, Irem Durmaz, Jönsson, Jenny-Maria, Hedenfalk, Ingrid
フォーマット: Artigo
言語:Inglês
出版事項: Impact Journals LLC 2019
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6916751/
https://ncbi.nlm.nih.gov/pubmed/31857852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27363
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!